ArticleTransfusion2026
Synergetic hemostatic potential of fibrinogen γ-chain peptide-coated, adenosine 5'-diphosphate-encapsulated liposomes combined with whole blood transfusion: A preclinical study.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWhole blood (WB) transfusions are being reevaluated because of their high hemostatic capacity and reduced volume. Fibrinogen γ-chain peptide-coated, adenosine 5'-diphosphate (ADP)-encapsulated liposomes are potent hemostatic adjuvants promoting platelet thrombi formation. This study aimed to elucidate the potential interactions between simultaneous WB transfusion and the administration of fibrinogen γ-chain peptide-coated ADP-encapsulated liposomes. STUDY DESIGN AND
methodsWe used a rabbit model of postcardiopulmonary bypass (CPB) coagulopathy. One hour after CPB, the rabbits were transfused with WB (WB group, n = 7) or H12-ADP-liposomes along with WB transfusion (WB + H12-ADP-liposome group, n = 7). Blood cell counts, coagulation activity, platelet function, and bleeding time were evaluated.
resultsHemoglobin concentration, platelet count, activated clotting time, and ADP and collagen test results were comparable between the WB + H12-ADP-liposome and WB groups after transfusion. However, bleeding time was remarkably reduced in the WB + H12-ADP-liposome group (378 ± 150 s) compared with that in the WB group (551 ± 255 s, p < .01), suggesting that H12-ADP-liposomes further enhanced the hemostatic effect of WB transfusion in post-CPB coagulopathy. DISCUSSION: Administration of H12-ADP-liposomes along with WB transfusion had a synergistic effect on hemostatic performance, providing a greater therapeutic advantage than WB transfusion alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.